醒脑静联合尤瑞克林治疗急性脑梗死的Meta分析

Meta-Analysis of Xingnaojing Combined with Urinary Kallidinogenase In Acute Cerebral Infarction Treatment

目的:评价醒脑静联合尤瑞克林治疗急性脑梗死的临床疗效及安全性。方法:计算机检索PubMed、Embase、Web of Science、知网、万方、维普等数据库,分析醒脑静联合尤瑞克林(试验组)、单纯尤瑞克林(对照组)治疗脑梗死的相关文献,并对文献进行系统评价,以RevMan5.3软件进行统计学分析。结果:共纳入12篇文献,总计990例患者。①临床疗效:神经功能学评分[(neurological deficit score,NDS)(RR=1.26,95%CI(1.17,1.36)),P<0.00001];美国国立卫生研究院卒中量表(national institutes of health stroke scale,NIHSS)评分[RR=1.26,95%CI(1.17,1.36),P<0.00001]。②神经功能评分:NIHSS评分中度组[MD=-2.23,95%CI(-2.48,-1.98),P<0.00001],NIHSS评分重度组[MD=-6.62,95%CI(-7.25,-5.99),P<0.00001];NDS:[MD=-3.48,95%CI(-3.76,-3.20),P<0.00001]。③生化指标:血清超氧化物歧化酶[MD=22.60,95%CI(18.52,26.68),P<0.00001];血清丙二醛[MD=-4.15,95%CI(-4.40,-3.90),P<0.00001]。④血液流变学指标:红细胞聚集指数[MD=-0.29,95%CI(-0.42,-0.15),P<0.0001],全血黏度[MD=-0.17,95%CI(-0.22,-0.12),P<0.00001],血浆黏度[MD=-0.32,95%CI(-0.50,-0.15),P=0.0003]。⑤不良反应:不良反应发生率[RR=1.00,95%CI(0.54,1.84),P=1.00]。结论:醒脑静联合尤瑞克林治疗急性脑梗死疗效优于单用尤瑞克林,两者在安全性方面无显著差异。

Objective:To assess the effects and safety of Xingnaojing combined with urinary Kallidinogenase in the treatment of acute cerebral infarction.Methods:PubMed,EMBASE,Web of Science,CNKI,Wanfang,VIP,and other databases were searched by computer and relevant research results meeting the requirements were collected:treating cerebral infarction with Xingnaojing combined with urinary Kallidinogenase as the test group while using urinary Kallidinogenase alone in the treatment as the control group,and the literature was systematically evaluated and statistically analyzed by Revman 5.3 software.Results:990 patients were included in the total of 12 selected articles.Data are as follows:①Clinical efficacy:Neurological Deficit Score(NDS):RR=1.26,95%CI(1.17,1.36),P<0.00001;National Institutes of Health Stroke Scale(NIHSS)score:RR=1.26,95%CI(1.17,1.36),P<0.00001.②Neurological function score:NIHSS score moderate group:MD=-2.23,95%CI(-2.48,-1.98),P<0.00001,NIHSS score severe group:MD=-6.62,95%CI(-7.25,-5.99),P<0.00001;NDS:MD=-3.48,95%CI(-3.76,-3.20),P<0.00001.③Biochemical indicators:serum superoxide dismutase:MD=22.60,95%CI(18.52,26.68),P<0.00001;serum malondialdehyde:MD=-4.15,95%CI(-4.40,-3.90),P<0.00001.④Hemorheology indicators:erythrocyte aggregation index:MD=-0.29,95%CI(-0.42,-0.15),P<0.0001,whole blood viscosity:MD=-0.17,95%CI(-0.22,-0.12)),P<0.00001,plasma viscosity:MD=-0.32,95%CI(-0.50,-0.15),P=0.0003.⑤Incidence of adverse reactions:RR=1.00,95%CI(0.54,1.84),P=1.00.Conclusion:Xingnaojing combined with urinary Kallidinogenase is better than urinary Kallidinogenase alone in the treatment of acute cerebral infarction,however,there is no significant difference in safety between the two.